Marin Kollef, MD, discusses recently approved agents targeting antibiotic resistant gram-negative bacteria and what to expect in the next 5 years.
Interview transcript (modified slightly for readability):
The new treatment options for antibiotic-resistant gram-negative bacteria primarily center around new antibiotics that have been developed. The new antibiotics that have been approved to date include several agents, including some combination drugs, 1 of which I’m describing here at the ECCMID meeting, which is ceftolozane/tazobactam.
There are other agents, as well, that have been approved recently and there are a number of other new drugs coming. So we’ll see probably about 10 new antibiotics that will have been developed for targeting antibiotic-resistant gram-negative bacteria over the next 5 years and into the next 5 to 7 years.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Subscribe
